Atividade antiandrogênica no tratamento da hiperplasia prostática benigna com nanocarreadores transdérmicos de dose combinada (tansulosina e dutasterida) / Antiandrogenic activity in Benign Prostatic Hyperplasia treatment with combined nanocarriers transdermal dose (tamsulosin and dutasteride)

Benign prostatic hyperplasia (BPH) is one of the most common diseases of the urogenital tract. Thisstudy aimed to obtain one transdermal microemulsion of dutasteride and tamsulosin, drugs used in the treatmentof BPH, characterize them and study your in vitro release, evaluating through in vivo studies the antiandrogenicactivity of transdermal microemulsion. The preparation of the formulation involved obtaining the microemulsionwith Dutasteride and Tamsulosin in the equivalent percentage of 0.2% for each drug. To carry out theantiandrogenic activity, were used 32 rats (Wistar) in four groups experimental. The characterization performedall formulations showed good results, in which the evaluation of anti-hyperplastic the microemulsiondemonstrated one reducing the organs testosterone-dependent (prostate and seminal vesicles) corroborated forthe study in question enabling then obtaining promising transdermal formulations for BPH treatment, presentingthus a therapeutic alternative to conventional treatments.(AU)

Atividade antiandrogênica no tratamento da hiperplasia prostática benigna com nanocarreadores transdérmicos de dose combinada (tansulosina e dutasterida) / Antiandrogenic activity in Benign Prostatic Hyperplasia treatment with combined nanocarriers transdermal dose (tamsulosin and dutasteride)

Benign prostatic hyperplasia (BPH) is one of the most common diseases of the urogenital tract. Thisstudy aimed to obtain one transdermal microemulsion of dutasteride and tamsulosin, drugs used in the treatmentof BPH, characterize them and study your in vitro release, evaluating through in vivo studies the antiandrogenicactivity of transdermal microemulsion. The preparation of the formulation involved obtaining the microemulsionwith Dutasteride and Tamsulosin in the equivalent percentage of 0.2% for each drug. To carry out theantiandrogenic activity, were used 32 rats (Wistar) in four groups experimental. The characterization performedall formulations showed good results, in which the evaluation of anti-hyperplastic the microemulsiondemonstrated one reducing the organs testosterone-dependent (prostate and seminal vesicles) corroborated forthe study in question enabling then obtaining promising transdermal formulations for BPH treatment, presentingthus a therapeutic alternative to conventional treatments.